Strides Pharma Sciences shares surged 10% to ₹988.70 during Thursday's trading session, demonstrating strong market confidence following the company's announcement of receiving the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its flagship Bengaluru facility. According to The Economic Times, the stock hit a 52-week high of ₹1,231.45 on May 12, 2026, with trading volumes jumping over fourfold as investors responded positively to the regulatory closure. The successful inspection closure further strengthens Strides' regulatory track record and reinforces the company's commitment to supplying high-quality pharmaceutical products to patients across global markets.
Strides Pharma's flagship formulations facility in Bengaluru has successfully received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA), marking the closure of the inspection conducted at the facility. The USFDA conducted a current Good Manufacturing Practices (cGMP) inspection from May 12 to May 20, 2026, which concluded with a Form 483 containing five observations as previously disclosed by the company. The receipt of the EIR with a Voluntary Action Indicated (VAI) classification indicates the successful closure of the inspection and resolution of all regulatory concerns. Strides Pharma Science announced the receipt of the EIR on August 19, 2026, confirming the successful closure of the inspection process for its flagship site. The Bengaluru plant is Strides' flagship manufacturing facility and produces a broad portfolio of pharmaceutical dosage forms, including tablets, capsules and oral liquids, supporting both existing commercial products and future growth opportunities. The facility caters to regulated markets, including the US, with sales of around $250 million from these markets.
The company has delivered robust financial results for Q1 FY27, with consolidated net profit jumping 56.7% year-on-year to ₹165.5 crore on a 13% increase in net sales to ₹1,265.4 crore compared to Q1 FY26. As reported by CNBC TV18, growth was supported by its Ex-US markets, where revenue rose 17% to ₹587.5 crore, while US revenue increased 4% to ₹628.2 crore. The strong performance demonstrates the company's operational efficiency and market demand for its pharmaceutical products. EBITDA grew 5.4% year-on-year to ₹230 crore, though EBITDA margin narrowed to 18% from 19.5% a year earlier. The company attributed the margin pressure to higher operating and freight costs related to the ongoing geopolitical situation, impacting profitability by around ₹13.1 crore.
As reported by The Economic Times, Strides Pharma Science submitted a comprehensive response addressing all five observations within the stipulated timeline. Based on the company's response and the corrective and preventive actions implemented, the USFDA classified the inspection outcome as Voluntary Action Indicated (VAI). The VAI classification denotes that while the agency may have noted minor observations, no mandatory corrective actions are required from the company, distinguishing it from the more stringent Official Action Indicated status. The USFDA subsequently issued the EIR, thereby concluding the inspection at the Bengaluru facility. A Form 483 represents observations made during the inspection and is issued by USFDA inspectors post completion, but does not represent a final FDA determination regarding the facility's GMP compliance.
According to NSE data, as of August 20, 2026, Strides Pharma has a total market capitalisation of ₹9,106.66 crore. The stock has demonstrated strong performance with gains of 8% from the beginning of the year, though it has slipped 7% over the past month and surged 14% in the past six months. From the beginning of the year, Strides Pharma shares have gained 8%, while over a month's time, the stock has slipped 7%, and it has surged 14% in the past six months. The company's diversified growth strategy, supported by investments in Ex-US markets and strategic acquisitions, positions it well for continued growth in regulated international markets.
